Status:
UNKNOWN
Safety & Efficacy of Extended Longevity Protocol
Lead Sponsor:
TruDiagnostic
Conditions:
Aging
Eligibility:
All Genders
55-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to quantifiably determine if the Extended Longevity Protocol has a significant clinical effect on epigenetic age.
Detailed Description
This is a prospective non-randomized clinical study of 15 patients to determine if the safety and effectiveness of the Extended Longevity Protocol's impact on the nine determinant factors of aging can...
Eligibility Criteria
Inclusion
- 8 Men and 7 Women
- Must between 55-75 years old
- Patient must be able to comply with treatment plan and laboratory tests
- Patients must have adequate immune system function, with no known immunodeficiency disease
Exclusion
- Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
- No immune system issues or immunodeficiency disease
- No history of viral illness which could be reactivated by immune downregulation
- Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease
- Diagnosis of a transient ischemic attack in the 6 months prior to screening
- Patients infected with hepatitis, C or HIV
- Patients with Body Mass Index (BMI) \> 40 kg/m2
- Presence of active infection
- Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
- Unable or unwilling to provide required blood sample for testing
Key Trial Info
Start Date :
May 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05296993
Start Date
May 25 2021
End Date
December 1 2023
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quantum Functional Medicine
Carlsbad, California, United States, 92008